29 Resultaterne viste, at behandling med losartan (327 hændelser) sammenlignet med placebo (359 hændelser) gav 16, 1% risikoreduktion (p=0, 022) for, at patienter nåede det primære, samlede effektmål.
The results showed that the treatment with Losartan (327 events) as compared with placebo (359 events) resulted in a 16.1% risk reduction (p = 0.022) in the number of patients reaching the primary composite endpoint.